Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

NCT01790295 is registered in ClinicalTrials.gov with John Mascarenhas as lead sponsor.

NCT NCT01790295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01790295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Lead sponsor
John Mascarenhas
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2013
Completion date
October 26, 2017
Enrollment
21 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

post essential thrombocythemia myelofibrosis, post polycythemia vera myelofibrosis, primary myelofibrosis